|
|
|
|
|
|
Companies > Clinical
|
|
|
Athersys (NASDAQ: ATHX) is a fully integrated pre-clinical, product discovery and development company with multiple synthetic pharmaceutical programs focused on obesity, cognition and other CNS disorders and asthma. The company also has a major effort in regenerative medicine (cell therapy). Using its MultiStem ™ platform (Multipotent Adult Progenitor Cells), the company has multiple programs focused on cardiovascular disease, neurology, hematological and immune disorders and a range of other indications.
Funders:
Aspire Capital, Radius Ventures, Orbimed, MPM, Hambrecht & Quist, A.M. Pappas Ventures, RA Capital Management, Accipiter Capital, Angiotech, Blue Chip, Invesco, Primus, Western Technology.
|
|
|
|
|